Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)

Technology appraisal guidance
Published: 30 April 2024

www.nice.org.uk/guidance/ta969
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)

Contents

Advice........................................................................................................................................ 3
Information.................................................................................................................................... 3
Advice

NICE is unable to make a recommendation about the use in the NHS of gefapixant for treating refractory or unexplained chronic cough. This is because Merck Sharp & Dohme has confirmed that it does not intend to make an evidence submission for the appraisal. Merck Sharp & Dohme considers that there is not enough evidence to provide an evidence submission for this appraisal. This is because of a lack of evidence on healthcare resource use during diagnosis and treatment of refractory or unexplained chronic cough.

Information

If NHS organisations wish to consider gefapixant for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6077-4